B. Riley analyst Mayank Mamtani lowered the firm’s price target on Pharmaceuticals to $55 from $59 and keeps a Buy rating on the shares. The analyst says the company’s pipeline disclosures were not as worse as feared.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARWR: